• Stephen Hauser, MD

    University of California, San Francisco

  • Christopher LaGanke, MD

    North Central Neurology Associates, P.C.

  • James Stankiewicz, MD

    Harvard Medical School Partners MS Center

  • Heidi Crayton, MD

    MS Center of Greater Washington

  • Jennifer Smrtka, MSN, ARNP‑BC, MSCN

    Fusion Health LLC

  • Stephen Hauser, MD

    University of California, San Francisco

  • Christopher LaGanke, MD

    North Central Neurology Associates, P.C.

  • James Stankiewicz, MD

    Harvard Medical School
    Partners MS Center

  • Heidi Crayton, MD

    MS Center of Greater Washington

  • Jennifer Smrtka, MSN, ARNP‑BC, MSCN

    Fusion Health LLC

  • Current Insights on MS Disease Activity and Progression

    Christopher LaGanke, MD — A conversation on the MS clinical course model, with evidence suggesting that subclinical disease activity and clinical progression reflect ongoing inflammatory or neurodegenerative processes.

  • Implications of Early Subclinical Lesions

    James Stankiewicz, MD — Insight into white and gray matter lesions and the implications of these frequent, extensive, and early subclinical lesions on cognitive dysfunction and disease progression.

  • Changing Perceptions of Immune Mediators in MS

    Christopher LaGanke, MD — Gain new perspectives on the role of immune cells, including B and T cell types, and their implications in CNS injury and the autoimmune response in MS.

  • Immune Mediators and the Inflammatory Process of MS

    Stephen Hauser, MD — T cells and B cells are integral mediators in the course of MS. Learn more about the role of of B and T cells in MS pathophysiology and inside the CNS itself, and their impact on subclinical disease activity in both white and gray matter lesions.

  • MS Question-and-Answer Session

    Stephen Hauser, MD — Watch Dr. Hauser as he answers audience questions from the live broadcast.

  • Evolving Perspectives in Multiple Sclerosis Disease Activity

    Heidi Crayton, MD and Jennifer Smrtka, MSN, ARNP-BC, MSCN — A discussion on the importance of subclinical disease in MS and its impact on disease worsening and disability progression. These experts also highlight the assessment of subclinical disease and discuss how it is detected.

Attend Live Expert MS Discussions

To participate in future programs, sign up by using this online RSVP calendar.

RSVP for Programs
  • Previous video

    Current Insights on MS Disease Activity and Progression

    Christopher LaGanke, MD — A conversation on the MS clinical course model, with evidence suggesting that subclinical disease activity and clinical progression reflect ongoing inflammatory or neurodegenerative processes.

    Next video
  • Previous video

    Implications of Early Subclinical Lesions

    James Stankiewicz, MD — Insight into white and gray matter lesions and the implications of these frequent, extensive, and early subclinical lesions on cognitive dysfunction and disease progression.

    Next video
  • Previous video

    Changing Perceptions of Immune Mediators in MS

    Christopher LaGanke, MD — Gain new perspectives on the role of immune cells, including B and T cell types, and their implications in CNS injury and the autoimmune response in MS.

    Next video
  • Previous video

    Immune Mediators and the Inflammatory Process of MS

    Stephen Hauser, MD — T cells and B cells are integral mediators in the course of MS. Learn more about the role of of B and T cells in MS pathophysiology and inside the CNS itself, and their impact on subclinical disease activity in both white and gray matter lesions.

    Next video
  • Previous video

    MS Question-and-Answer Session

    Stephen Hauser, MD — Watch Dr. Hauser as he answers audience questions from the live broadcast.

    Next video
  • Previous video

    Evolving Perspectives in Multiple Sclerosis Disease Activity

    Heidi Crayton, MD and Jennifer Smrtka, MSN, ARNP-BC, MSCN — A discussion on the importance of subclinical disease in MS and its impact on disease worsening and disability progression. These experts also highlight the assessment of subclinical disease and discuss how it is detected.

    Next video